subject area of
- A Phase II Trial of Erlotinib and Concurrent Palliative Thoracic Radiation for Patients With Non–Small-Cell Lung Cancer Academic Article
- Cost-Effectiveness Analysis of Afatinib, Erlotinib, and Gefitinib as First-Line Treatments for EGFR Mutation-Positive Non-Small-Cell Lung Cancer in Ontario, Canada Academic Article
- Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome Academic Article
- Method to Our Madness or Madness in Our Methods? Pitfalls in Trial Methodology Academic Article
- Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLC Academic Article
- Osimertinib in UntreatedEGFR-Mutated Advanced Non–Small-Cell Lung Cancer Academic Article
- Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC Academic Article
- Phase 2 Study of Erlotinib in Combination With Linsitinib (OSI-906) or Placebo in Chemotherapy-Naive Patients With Non–Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations Academic Article
- Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors Academic Article
- Phase I Targeted Combination Trial of Sorafenib and Erlotinib in Patients with Advanced Solid Tumors Academic Article
- Phase I/II Trial of Erlotinib and Cisplatin in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: A Princess Margaret Hospital Phase II Consortium and National Cancer Institute of Canada Clinical Trials Group Study Conference Paper
- Phase II Study of Erlotinib in Recurrent or Metastatic Endometrial Cancer: NCIC IND-148 Academic Article
- Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer Academic Article
- Predictive and Pharmacodynamic Biomarker Studies in Tumor and Skin Tissue Samples of Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Treated With Erlotinib Academic Article
- Role of KRAS and EGFR As Biomarkers of Response to Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21 Academic Article
- Targeted Inhibition of EGFR and Glutaminase Induces Metabolic Crisis in EGFR Mutant Lung Cancer Academic Article
- Targeted Therapy– and Chemotherapy-Associated Skin Toxicities: Systematic Review and Meta-Analysis Academic Article
- Targeting the epidermal growth factor receptor in non-small-cell lung cancer: Who, which, when, and how? Academic Article
- Thymic Epithelial Tumors phenotype relies on miR-145-5p epigenetic regulation Academic Article